Work

Initial Results of a Phase 1 Dose Escalation Study of LP-168, a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase

Year: 2023

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2023-186432

Authors: Jennifer A. Woyach, Deborah M. Stephens, Danielle M Brander, Adam S Kittai, Boyu Hu, Andrea Sitlinger, Emily K Curran, Fenlai Tan, Yi Chen, Stephen P. Anthony, Yu Chen, John C. Byrd

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University of Utah, Huntsman Cancer Institute, Duke Medical Center, Duke Cancer Institute, The Ohio State University, University of Cincinnati

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4389247648

Cites:

Cited by: 11

Related to: 10